Galapagos and Gilead Sciences have both evolved since inking their R&D collaboration agreement in 2019. Separating Galapagos into two offers a way for that company to pursue its cell therapy strategy while also keeping the Gilead alliance alive, executives from both companies said.
The post Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation appeared first on MedCity News.
Leave a comment